1st Quarter - Report

BAXTER HEALTHCARE CORPORATION for BAXTER HEALTHCARE CORPORATION

Firm
Client
Income
—
Expenses
$350,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Issues related to pharmaceutical pricing. Issues related to drug shortages.

LobbyistCovered position, as disclosed
MARK COIN —
JACK MANIKO —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

Issues relating to drug pricing, 340B Drug pricing, device sterilization. Issues relating to safe mobility and issues relating to diabetic retinopathy. Issues relating to pandemic preparedness act. Issues related to artificial intelligence technology in healthcare; issues related to Hurricane Helene.

LobbyistCovered position, as disclosed
CADE CLURMAN —
MARK COIN —
JACK MANIKO —
JOSEPH V SCHWAN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Budget/Appropriations BUD

Issues related to increasing funding for Strategic National Stockpile. Labor, Health, and Human Services appropriations.

LobbyistCovered position, as disclosed
CADE CLURMAN —
MARK COIN —
JACK MANIKO —
JOSEPH V SCHWAN —

Taxation/Internal Revenue Code TAX

Taxation of multinational companies. Monitor tax reform proposal relating to corporate tax policies.

LobbyistCovered position, as disclosed
CADE CLURMAN —
JOSEPH V SCHWAN —

Contacted: Treasury, Dept of

Trade (domestic/foreign) TRD

None.

LobbyistCovered position, as disclosed
CADE CLURMAN —
MARK COIN —
JACK MANIKO —
JOSEPH V SCHWAN —

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.